Prevalence of Malignant Hyperthermia Due to Anesthesia in New York State, 2001–2005

Brady, Joanne E.; Sun, Lena S.; Rosenberg, Henry; Li, Guohua

doi:10.1213/ane.0b013e3181ac1548

Cited by 134 publications

(110 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Episodes of MH occur predominantly in young, muscular males. 21,22 All ethnicities are affected. The estimated incidence of MH is 1 in 250 000 surgeries involving all types of anesthesia and 1 in 62 000 uses of potent inhalational anesthetics or succinylcholine.…”

Section: Definition Of Malignant Hyperthermiamentioning

confidence: 99%

See 1 more Smart Citation

Round Table on Malignant Hyperthermia in Physically Active Populations: Meeting Proceedings

Hosokawa

Casa

Rosenberg

et al. 2017

Journal of Athletic Training

Self Cite

View full text Add to dashboard Cite

Context: Recent case reports on malignant hyperthermia (MH)-like syndrome in physically active populations indicate potential associations among MH, exertional heat stroke (EHS), and exertional rhabdomyolysis (ER). However, an expert consensus for clinicians working with these populations is lacking.Objective: To provide current expert consensus on the (1) definition of MH; (2) history, etiology, and pathophysiology of MH; (3) epidemiology of MH; (4) association of MH with EHS and ER; (5) identification of an MH-like syndrome; (6) recommendations for acute management of an MH-like syndrome; (7) special considerations for physically active populations; and (8) future directions for research. Setting: An interassociation task force was formed by experts in athletic training, exercise science, anesthesiology, and emergency medicine. The ''Round Table on Malignant Hyperthermia in Physically Active Populations'' was convened at the University of Connecticut, Storrs, September 17-18, 2015.Conclusions: Clinicians should consider an MH-like syndrome when a diagnosis of EHS or ER cannot be fully explained by clinical signs and symptoms presented by a patient or when recurrent episodes of EHS or ER (or both) are unexplained. Further research is required to elucidate the genetic and pathophysiological links among MH, EHS, and ER.

show abstract

Section: Definition Of Malignant Hyperthermiamentioning

confidence: 99%

“…The estimated incidence of MH is 1 in 250 000 surgeries involving all types of anesthesia and 1 in 62 000 uses of potent inhalational anesthetics or succinylcholine. 23 In a study 21 of New York hospitals, the prevalence rate of MH was 0.96 per 100 000 surgical discharges. 2.…”

Section: Definition Of Malignant Hyperthermiamentioning

confidence: 99%

Round Table on Malignant Hyperthermia in Physically Active Populations: Meeting Proceedings

Hosokawa

Casa

Rosenberg

et al. 2017

Journal of Athletic Training

Self Cite

View full text Add to dashboard Cite

show abstract

“…Con respecto a la inci-dencia de la enfermedad se estima en 1 en 15.000 anestesias en niños y adolescentes y 1 en 50.000 a 150.000 anestesias en adultos 4 . Sin embargo, existen grandes variaciones en las tasas de incidencias publicadas, probablemente debidas tanto a la diversidad geográfica, a los diferentes métodos diagnósticos utilizados, a la falta de reporte como a los diferentes denominadores usados en los diversos estudios [5][6][7][8][9] . En un estudio reciente Brady y cols 9 , reportaron una prevalencia de 0,96 por cada 100.000 procedimientos quirúrgicos.…”

Section: Incidenciaunclassified

Hipertermia maligna: ¿cómo estar preparados?

A¹,

M²,

B³

2013

Rev Chil Cir

View full text Add to dashboard Cite

Malignant hyperthermia: how to be prepared?Malignant hyperthermia is an autosomal dominant genetic disease that affects the skeletal muscle. Specifically corresponds to a hypermetabolic response against triggering agents such as halogenated gases and the muscle relaxant succinylcholine. Because MH is a potentially fatal disease and ocurrs unexpectedly during a surgery, it is important to stablish how should be the perioperative management of these patients. The aim of this review is to present the current knowledge about the incidence, pathophysiology and triggers of malignant hyperthermia in addition to concepts for the safe management of these patients.Key words: Malignant hyperthermia, susceptible, diagnosis. ResumenLa hipertermia maligna es una enfermedad genética autosómica dominante que afecta al músculo esquelético. Específicamente corresponde a una respuesta hipermetabólica frente a agentes gatillantes como los gases halogenados y el relajante muscular succinilcolina. Debido a que la HM es una enfermedad potencialmente letal e inesperada, que ocurre durante una cirugía, es importante establecer claramente como debe ser el manejo perioperatorio de estos pacientes. El objetivo de esta revisión es presentar los conocimientos actuales sobre la incidencia, fisiopatología y factores desencadenantes de la hipertermia maligna, además de conceptos para el manejo seguro de estos pacientes.Palabras claves: Hipertermia maligna, susceptibles, diagnóstico. Generalidades DefiniciónLa hipertermia maligna (HM) es una enfermedad genética autosómica dominante que afecta al mús-culo esquelético. Específicamente corresponde a una respuesta hipermetabólica frente a agentes gatillantes como los gases halogenados, el relajante muscular succinilcolina y raramente en humanos frente a ejercicio vigoroso y calor [1][2][3] . IncidenciaLa HM es una enfermedad de baja ocurrencia, pero potencialmente fatal. Con respecto a la inci-

show abstract

“…[4][5][6] El SHM puede presentarse en forma rápida, en la inducción anestésica, relacionado con el uso de succinilcolina y asociado a rigidez muscular y mayor repercusión orgánica, o en forma tardía, en la anestesia o posteriormente, asociado al uso de agentes inhalatorios halogenados (sevoflurano, isoflurano, halotano y enflurano), y puede ocurrir con o sin rigidez y variabilidad en la magnitud del compromiso orgánico. También pueden existir formas de presentación abortivas o menores.…”

Section: Introductionunclassified

Síndrome de hipertermia maligna: a propósito de un caso clínico

Taffarel

Koffman²,

Zifferman

et al. 2015

Arch Argent Pediat

View full text Add to dashboard Cite

Arch Argent Pediatr 2015;113(2):e113-e116 / e113Presentación de casos clínicos RESUMEN El síndrome de hipertermia maligna es una miopatía familiar de naturaleza farmacogenética, que se presenta como un síndrome hipercatabólico del músculo esquelético ligado a la anestesia. La incidencia en pediatría es de 1 cada 10 000 cirugías. Puede ser de instalación rápida, asociado a succinilcolina, o tardía, relacionado con agentes inhalatorios. El cuadro ocurre con taquicardia, hipertermia, hipercapnia, acidosis, rigidez muscular, hiperpotasemia, falla renal y arritmia. La mortalidad sin tratamiento específico es del 80% y desciende al 7% con el uso de dantroleno sódico. Reportamos el caso de un paciente de 8 años que se internó para cirugía de fimosis. Por presentar taquicardia, hipercapnia y rigidez muscular, se inició tratamiento con dantroleno sódico en quirófano, el cual se mantuvo durante 72 h. Evolucionó las primeras 12 h con bajo gasto cardíaco, con máximo valor de creatina fosfoquinasa de 155 147 U/L. Permaneció con asistencia mecánica respiratoria por 48 h. Se otorgó alta al sexto día, sin secuelas. Palabras clave: hipertermia maligna, dantroleno sódico, creatina fosfoquinasa. ABSTRACTMalignant hyperthermia syndrome is a family myopathy of pharmacogenetic nature, which appears as a skeletal muscle hypercatabolic syndrome linked to anesthesia. The incidence in pediatrics is 1 event per 10 000 surgeries. The clinical picture may have a rapid onset associated with succinylcholine, or a late onset related to inhalation agents. The clinical picture includes tachycardia, hyperthermia, hypercapnia, acidosis, muscle rigidity, hyperkalemia, renal failure and arrhythmia. Mortality without specific treatment is of 80% and drops to 7% with the use of dantrolene sodium. We report an 8-year-old patient admitted for phimosis surgery; having tachycardia, hypercapnia and muscle rigidity, he started treatment with dantrolene sodium in the operating room, which was maintained for 72 hours. He evolved the first 12 hours with low cardiac output and creatine phosphokinase maximum of 155 147 U/L. He remained with mechanical ventilation for 48 hours. Discharge was given on the sixth day without sequelae.

show abstract

Prevalence of Malignant Hyperthermia Due to Anesthesia in New York State, 2001–2005

Abstract: The prevalence of MH due to anesthesia in surgical patients treated in New York State hospitals is approximately 1 per 100,000. MH risk in males is significantly higher than in females.

Cited by 134 publications

References 22 publications

Round Table on Malignant Hyperthermia in Physically Active Populations: Meeting Proceedings

Round Table on Malignant Hyperthermia in Physically Active Populations: Meeting Proceedings

Hipertermia maligna: ¿cómo estar preparados?

Síndrome de hipertermia maligna: a propósito de un caso clínico

Contact Info

Product

Resources

About